First Trust Switzerland AlphaDEX FundFSZ

FSZ is a First Trust Switzerland AlphaDEX Fund listed on Nasdaq, promising to deliver Swiss equity exposure with a systematic tilt toward growth and value factors, all wrapped in an actively managed index disguise. The fund’s mandate is to track the NASDAQ AlphaDEX Switzerland Index, a rules-based selection of Swiss stocks screened for liquidity and then ranked on growth and value metrics before being weighted accordingly. In practice, this means FSZ holds a portfolio that is neither fish nor fowl: not pure Swiss large caps, not a growth-only tilt, but a rules-driven compromise that changes every time the methodology runs its quarterly screen. (source: Nasdaq, https://www.nasdaq.com/market-activity/etf/fsz)

The fund’s expense ratio is 0.60%, a fee that sounds reasonable until you remember it’s being charged on a basket that will shuffle its holdings every three months like a deck of cards in a Zurich casino. First Trust markets FSZ as a way to capture Swiss alpha, but the AlphaDEX methodology is the real star, and it’s not infallible-it’s just a set of rules that can rotate out of last quarter’s winners faster than a waiter can spill fondue. (source: Nasdaq, https://www.nasdaq.com/market-activity/etf/fsz)

FSZ files under SEC rule 481, which governs periodic reporting and disclosure requirements for registered investment companies. The fund’s regulatory home is the SEC’s EDGAR database, where its registration statements and subsequent filings live under the ticker FSZ. The filings confirm the fund’s structure, fees, and methodology, but they do not reveal the actual holdings or performance-those are left to the issuer’s discretion and updated on the fund’s website. In short, the SEC gives FSZ a filing home; the fund’s website gives you the current holdings and fact sheet. (source: SEC EDGAR, https://www.sec.gov/edgar/search/#/q=FSZ)

The fund’s liquidity is tracked on Nasdaq, where FSZ trades under the same ticker, and FINRA’s Fund Analyzer tool confirms the fund’s expense ratio and basic structure. There are no surprises here: FSZ is a plain-vanilla ETF wrapper around a rules-based Swiss equity index, with a fee that sits at 0.60% and a mandate that promises alpha without guaranteeing it. If you want Swiss exposure, you’re buying the method; if you want to pay for it, you’re paying the fee. (source: FINRA Fund Analyzer, https://tools.finra.org/fund_analyzer/)

What changed this week? Nothing structural. FSZ’s holdings will rebalance again in the next quarterly cycle, but that’s par for the course for an AlphaDEX fund. The fund’s price and volume data are visible on Nasdaq, but neither the exchange nor FINRA’s tools reveal whether the recent rebalancing improved or worsened the portfolio’s tilt. Without the actual holdings or performance metrics in the public domain, the only concrete facts are the fee and the mandate-and neither of those has moved. (source: Nasdaq, https://www.nasdaq.com/market-activity/etf/fsz; FINRA Fund Analyzer, https://tools.finra.org/fund_analyzer/)

What remains unproven is whether the AlphaDEX methodology actually delivers alpha. The fund’s prospectus promises relative strength versus a cap-weighted Swiss index, but the proof is in the pudding-and the pudding is locked in the fund’s quarterly fact sheets, which are not part of the SEC filings and must be hunted down on First Trust’s website. Until those fact sheets show persistent relative strength after fees, FSZ’s marketing pitch remains a promise wrapped in a fee. (source: Nasdaq, https://www.nasdaq.com/market-activity/etf/fsz)